Trial Profile

A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pafolacianine (Primary)
Indications Ovarian cancer
Focus Adverse reactions; Diagnostic use
Sponsors On Target Laboratories

Most Recent Events

15 Oct 2019 According to an On Target Laboratories media release, results of this study were published in Gynecologic Oncology Journal.
15 Oct 2019 Results presented in an On Target Laboratories media release.
27 Jul 2019 Results assessing safety and efficacy of OTL-38 in patients with ovarian cancer patients, published in the Gynecologic Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com